Try Calculator
← Back to Articles DOSAGE PROTOCOL

Tesamorelin: A Complete User’s Guide to the FDA-Approved GHRH Analog for Visceral Fat, Liver Fat, and Growth Hormone Optimization

Most peptides in the growth-hormone conversation share one weakness: thin clinical data. Tesamorelin is the exception. It is the only peptide ever to win FDA approval specifically for reducing visceral fat, and it carries Phase 3 randomized trial evidence that no other compound in its category can match. This guide covers what it is, how it works, who it’s for, how it’s dosed and cycled, and—just as importantly—where the honest gaps in the evidence remain.

What Tesamorelin Actually Is

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH)—the upstream signal your hypothalamus uses to tell your pituitary to release your own growth hormone in natural, pulsatile bursts. The sequence matters here: you inject tesamorelin, your pituitary releases GH, and your liver responds by producing IGF-1. The negative feedback loops that keep this whole system balanced stay intact.

That distinction is the entire point. Tesamorelin is not growth hormone. Direct HGH injection bypasses your body’s regulatory machinery and floods the system from the outside. Tesamorelin works one step upstream, turning up the dial on a thermostat that remains active. Think of the hypothalamus as the dial, the pituitary as the furnace, GH as the heat, and IGF-1 as the room temperature. Tesamorelin turns up the dial—but the thermostat keeps doing its job, which is a meaningful safety advantage over exogenous GH.

The molecule

Tesamorelin is a 44-amino-acid peptide with a sequence identical to native human GHRH, plus one critical modification: a trans-3-hexenoic acid moiety attached to the alpha-amino group of the first amino acid (tyrosine). That addition physically blocks the enzyme DPP-4 from cleaving the molecule, which extends the half-life from roughly 7 minutes (native GHRH) to about 26–38 minutes—long enough to drive a meaningful GH pulse from a single daily injection.

It was developed by Theratechnologies in Montreal under the internal code TH9507. You’ll see it sold under the brand names Egrifta, then Egrifta SV (2014), and most recently Egrifta WR (2025). In compounding contexts it’s referred to as tesamorelin acetate, TH9507, or simply tesamorelin.

The Headline Numbers

Three figures define the evidence base:

No other peptide in this category has clinical trial data of this quality, and that’s the single most important thing to understand about why tesamorelin gets taken seriously when sermorelin, CJC-1295, and ipamorelin remain in the gray market.

Five Clinically Important Effects

  1. Visceral fat falls. GH-driven lipolysis preferentially targets the dangerous fat stored behind the abdominal wall.
  2. Liver fat falls. This comes from direct GH effects plus reduced fatty acid delivery as visceral fat shrinks.
  3. IGF-1 rises, restoring levels more typical of healthy young adulthood.
  4. Lipids improve. Triglycerides fall significantly; cholesterol improves modestly.
  5. Cognition may improve. Executive function improved in older adults in the Baker 2012 randomized controlled trial.

How It Compares to Other GH Peptides

Tesamorelin Sermorelin / CJC-1295 Ipamorelin / MK-677
Receptor GHRH receptor GHRH receptor Ghrelin receptor (GHSR)
Half-life 26–38 min ~30 min / 6–8 days (DAC) 2 hrs / ~24 hrs
FDA approval Yes No No
Visceral fat RCT data Phase 3 None None
Stackable with tesamorelin — Competes (same receptor) Additive

The practical takeaway: sermorelin and CJC-1295 compete with tesamorelin for the same GHRH receptor and shouldn’t be combined with it, while ipamorelin works through a different (ghrelin) receptor and is additive.

Who Tesamorelin Is For

The strongest candidates fall into a few clear profiles:

Creeping visceral fat (40s–50s). Training and diet are reasonable, but the midsection won’t respond. This is where the evidence base is strongest.

NAFLD / fatty liver. Elevated liver enzymes or an imaging diagnosis. This is the cleanest clinical trial data of any peptide for liver fat.

Low-normal IGF-1 (50+). People in the bottom third of the age-specific range, with poor recovery and drifting body composition. Tesamorelin raises IGF-1 by roughly 80–110% at the full dose.

Cognitive concerns (55+). Word-retrieval problems, slower executive function. The Baker 2012 RCT showed improvement over 20 weeks.

Two additional profiles come up often. A biohacker already optimized on TRT is a clean complement—testosterone drives muscle protein synthesis while tesamorelin amplifies the GH axis and handles visceral fat, two different signals working together. And the post-bariatric or post-GLP-1 patient who has lost significant weight but retains a disproportionate visceral depot can use tesamorelin to target that residual fat specifically, once stable on the primary intervention.

One critical framing point: tesamorelin is body recomposition, not weight loss. The FDA label explicitly notes a weight-neutral effect. If significant weight reduction is the goal, GLP-1 agonists are the right tool.

Who should skip it

Some contraindications are absolute:

Dosing: The Three-Tier Ladder

Dosing generally follows three tiers:

Tier 1 — 1 mg/day. General optimization, cognitive support, sleep, and gradual body composition change. IGF-1 rises roughly 40–70%. This is the best starting dose for clients in their 50s–60s.

Tier 2 — 2 mg/day. The FDA-approved dose, used in all the pivotal trials. IGF-1 rises 80–110%. This is the workhorse for visceral fat, liver fat, and substantive body composition change.

Tier 3 — 2 mg/day, extended. For established NAFLD or severe lipohypertrophy, run as 12-month continuous courses per the Stanley 2019 protocol.

Dosing by purpose

Goal Dose Duration / Cycle Key notes
Longevity / anti-aging 1 mg/day 8–12 wks on / 4–6 wks off 5 days/week; bedtime
Visceral fat reduction 2 mg/day 6–9 months on / 2–3 months off 26 wks minimum for full response
Liver fat / NAFLD 2 mg/day 12 months continuous Baseline FibroScan required
Athletic performance 1–2 mg/day Anchored to training block WADA-banned—not for tested athletes
Cognitive support (50+) 1 mg/day 20 weeks (Baker 2012 protocol) Bedtime dosing
Post-illness recovery 1 mg/day 8–12 weeks Mechanistic / anecdotal evidence

Timing, fasting, and frequency

Standard timing is once daily at bedtime, 1–2 hours after the last meal. This amplifies the largest natural GH pulse of the day, which occurs during slow-wave sleep. Fasted injection matters: carbohydrates and fats suppress GH release, so injecting on an empty stomach maximizes pulse amplitude. Morning dosing is acceptable for visceral fat reduction if bedtime interferes with sleep onset, but bedtime is preferred for IGF-1 and cognitive goals.

The most common optimization pattern is a 5-days-on / 2-days-off schedule. The two-day break gives the GHRH receptor a brief recovery window and reduces cumulative IGF-1 burden across the week. If you practice intermittent fasting, inject at the end of the fasting window, before the first meal of the eating window.

What to Expect: The Timeline

An honest caveat: if there’s no meaningful change by 16 weeks at 2 mg/day, you are likely a non-responder. About one-third of Phase 3 patients did not achieve significant visceral fat reduction.

How to know it’s working

Subjectively, between weeks 8 and 16, watch for better sleep depth and morning recovery, sharper executive function, a slow drop in waist circumference, more durable training capacity, and improved skin quality. Objectively, the markers that matter are IGF-1 (should rise 50–110% from baseline at 8–12 weeks), waist circumference (a 1–3 cm drop at 12 weeks), DEXA visceral fat (a measurable drop at 24 weeks), triglycerides, and ALT/AST if elevated at baseline.

Why Cycle at All?

Three reasons drive intelligent cycling:

  1. The evidence gap beyond 18 months. The longest published continuous-use trial is 12 months, with an open-label extension to roughly 18 months. Cycling errs on the side of caution.
  2. Assessing real durability. Off-cycle bloodwork reveals whether gains are durable or entirely peptide-driven.
  3. Antibody formation. Anti-tesamorelin IgG antibodies develop in about half of patients after 26 weeks. They were non-neutralizing in trials, but cycling breaks the exposure pattern.

Standard cycling patterns

Pattern On Off Best for
Short cycle 8 weeks 4 weeks General optimization, cognitive support, beginners
Middle-ground 12 weeks 4 weeks Most common general-purpose pattern
Visceral fat protocol 16–24 weeks 8–12 weeks Full visceral fat response from Phase 3 trials
NAFLD protocol 12 months Substantive break Established NAFLD (Stanley 2019)
Low-dose maintenance 1 mg/day continuous Quarterly monitoring Documented low IGF-1, cautious approach

Continuous use beyond 18 months in an optimization context means operating in an evidence-free zone. Take regular breaks until long-term data clarifies the picture.

Off-cycle expectations

The peptide is not a cure, and the visceral fat benefit is treatment-dependent. IGF-1 returns to baseline within 2–3 weeks. Sleep and recovery effects regress within a few weeks. Visceral fat holds for 4–8 weeks, then drifts back over the following 8–16 weeks. Lipid improvements regress more slowly. The off-cycle period is exactly where lifestyle work matters most.

Sequencing: Foundation First

A useful way to think about it: tesamorelin is infrastructure, not operations. Before the framers arrive, the foundation has to be poured and the slab cured. Insulin sensitivity, mitochondrial function, sleep, and hormone status all need to be in reasonable shape before GH-axis amplification produces its expected effects.

A suggested sequencing structure:

Doing the foundation first gives a clean baseline against which to measure peptide effects—and prevents the failure modes that show up when tesamorelin is started on a broken metabolic foundation. Run in reverse, glucose can go the wrong way (GH-axis amplification can push HbA1c higher in insulin-resistant clients), side effects like water retention and joint discomfort are amplified, and there’s no clean diagnostic to tell whether a non-response reflects the wrong peptide, the wrong dose, or a missing foundation.

Reconstitution and Administration

Tesamorelin ships lyophilized (freeze-dried) because peptides are unstable in liquid—they aggregate and lose potency within days at room temperature. Freeze-drying preserves stability for years under refrigeration.

Always reconstitute with bacteriostatic water, which contains 0.9% benzyl alcohol as a preservative and stays good for 14–28 days refrigerated after reconstitution. Plain sterile water is only good for same-day use.

Concentration quick reference

Vial / Recon Dose Draw
5 mg + 2 mL BW 1 mg 40 units
5 mg + 2 mL BW 2 mg 80 units
10 mg + 2 mL BW 1 mg 20 units
10 mg + 2 mL BW 2 mg 40 units

The formula: (mg dose ÷ mg/mL concentration) × 100 = units on a U-100 syringe.

Procedure. Wash hands and wipe both rubber stoppers with alcohol pads. Draw the bacteriostatic water with a 3 mL syringe. When adding it to the vial, angle the needle so the water runs down the inner wall—never squirt directly onto the powder, because foaming denatures the peptide. Swirl gently (do not shake); the powder dissolves in 30–90 seconds to a clear, colorless solution. Label with the reconstitution date and concentration, and refrigerate immediately.

Injection. Inject subcutaneously into the abdomen, at least two inches from the umbilicus (thigh or upper arm are also acceptable). Use a 29–31g insulin syringe, ½ inch or shorter. Pinch a fold, insert at 45–90°, inject over about 5 seconds, and apply gentle pressure for 10–15 seconds. Rotate sites in a four-quadrant pattern, returning to the same spot no more than once per week.

Storage. Lyophilized vials keep refrigerated at 2–8°C for 2–3 years. Reconstituted solution should be used within 14–28 days. Never freeze tesamorelin in any form—freezing destroys the peptide structure. Discard any vial that is cloudy, discolored, contains particulates, or has been accidentally frozen.

What to Track

Lab cadence runs baseline → 8–12 weeks → 24 weeks → quarterly for long cycles. The IGF-1 target is the upper third of the age-specific reference range—not above it.

Stacking Decisions

The foundational pairing is testosterone (TRT). TRT drives muscle protein synthesis; tesamorelin handles visceral fat and recovery. No dose adjustment is needed for either.

With GLP-1 agonists, the GLP-1 drives overall weight loss while tesamorelin selectively targets visceral fat. Monitor glucose at 8 and 16 weeks, and consider 1.4 mg instead of 2 mg to minimize the glucose effect.

With BPC-157 / TB-500 for injury recovery, the healing peptides handle local tissue repair while tesamorelin provides the systemic IGF-1 elevation that supports an anabolic context.

With SS-31 (elamipretide), the axes are complementary—SS-31 stabilizes mitochondrial membrane function while tesamorelin amplifies the GH axis. This is a strong pairing for older clients in longevity protocols.

Other acceptable combinations include KPV (inflammatory bowel or chronic inflammation plus visceral fat—different mechanisms, clean combination), NAD+ precursors (NMN/NR; mechanistically complementary but no trial data), Epitalon or Thymalin (different systems entirely), and ipamorelin (additive GH release via a different receptor, though the larger IGF-1 elevation increases side-effect burden, so monitor glucose more carefully).

Do not stack with:

Troubleshooting: “I Don’t Feel Anything”

This is the most common complaint in weeks 1–6, and it usually traces to one of five causes:

Side effect management

Side effect Timing Management
Injection site reactions Ongoing Rotate sites; skip reactive spots for 1 week
Water retention / puffiness Weeks 1–8 Usually resolves by week 12; reduce to 1 mg or every-other-day if persistent
Joint discomfort / stiffness Weeks 1–8 Improves as the system stabilizes; reduce dose if severe
Paresthesias (tingling) Early weeks Usually transient; reduce dose or discontinue if persistent
Mild glucose elevation Weeks 1–8 Monitor HbA1c; if no body comp response plus rising glucose, discontinue
Sleep onset interference Early Shift injection 1–2 hours before bedtime

When to discontinue

Absolute stop signals: new malignancy diagnosis, pregnancy (immediately), a hypersensitivity reaction, ALT/AST greater than 3× the upper limit of normal, or an IGF-1 z-score above +2 despite dose reduction.

Strong reconsideration signals: HbA1c rising more than 0.5% without a body composition response, persistent or worsening peripheral edema, persistent neuropathic symptoms, or 16 weeks with no measurable response at 2 mg/day.

Frequently Asked Questions

Can I take it orally or intranasally? No. Tesamorelin is destroyed by stomach acid within minutes—there’s no oral bioavailability—and the intranasal route hasn’t been studied. Subcutaneous injection only.

Will it make me gain weight? No. The FDA label states a weight-neutral effect: visceral fat decreases while lean mass is preserved. A transient 1–3 lb of water retention in weeks 1–6 resolves. Track waist circumference and DEXA, not the scale.

Does it affect ketosis? Not directly. GH drives lipolysis, which complements a ketogenic diet. The peptide and the diet work cleanly together.

Does it interact with TRT, metformin, or statins? No clinically significant interactions and no dose adjustment needed. Monitor glucose when adding tesamorelin to metformin.

Tesamorelin vs. CJC-1295 + ipamorelin? Tesamorelin has stronger evidence, a cleaner mechanism, and is the better choice for visceral fat and NAFLD. CJC + ipamorelin offers broader anti-aging effects, milder side effects, and lower cost. For visceral fat specifically, tesamorelin wins.

What happens when I stop? IGF-1 returns to baseline in 2–3 weeks; visceral fat drifts back over 8–24 weeks without other interventions. It’s a continuous intervention, not a cure.

Cancer history—ruled out forever? Active malignancy is an absolute contraindication. Stable remission warrants a conversation with your oncologist. The conservative position is to avoid it with a history of hormone-sensitive cancer (prostate, breast, colorectal).

How much does it cost? Brand-name Egrifta WR runs roughly $2,500–$5,500/month as cash-pay off-label. Compounded 503A pharmacy product is typically $200–$500/month. Research-grade material runs under $50/month but sits outside the prescription framework—which also means no oversight on identity, purity, or dose, and is why source verification matters so much.

The Future Outlook

A few active programs are worth watching. NCT03375788 (Stanley, Massachusetts General Hospital) is a non-HIV NAFLD trial, last updated September 2024, with primary results pending as of mid-2026; positive results would significantly expand the off-label rationale. The FDA-mandated 10-year malignancy cohort has not yet published and will substantially clarify long-term safety. A cognition trial (NCT02572323) is registered but has no primary publication yet.

As for where the field is heading: tesamorelin remains the FDA-approved GHRH analog of choice, and it’s increasingly used as a complementary tool layered onto GLP-1 protocols rather than as a standalone. The emerging advanced body composition stack—GLP-1 for overall weight loss, tesamorelin for visceral fat targeting, plus lean mass preservation—is likely to become a standard pattern. Oral GHRH receptor agonists are in early research, with none in clinical trials as of mid-2026.

The Evidence Base: What’s Solid, What’s Not

It’s worth being precise about the line between proven and presumed.

Strong evidence: 15–18% visceral fat reduction at 26 weeks (Phase 3 RCTs); 37% liver fat reduction at 12 months (Stanley 2019, Lancet HIV); 80–110% IGF-1 elevation at 2 mg/day; and executive function improvement in older adults (Baker 2012 RCT).

Honest gaps: the longest published RCT is only 12 months; the non-HIV NAFLD trial hasn’t reported; the 10-year malignancy cohort isn’t published; the cognitive evidence rests on one good RCT rather than a body of work; and there’s no RCT data in long COVID or chronic fatigue syndrome.

The Bottom Line

Tesamorelin works best when the foundation work is done first, the dose is matched to the goal, cycling is intelligent, and monitoring is honest. The right indications are clear: visceral fat in middle-aged adults, NAFLD, low-normal IGF-1 in adults over 50, and cognitive support in older adults. And the expectations should be realistic—about one-third of users are non-responders, it’s not a cure, and it’s not a weight loss drug. It’s a continuous intervention that requires monitoring and cycling.

Done right, in the right person, for the right indication, tesamorelin is one of the most useful and best-evidenced peptides available in 2026. It is a tool, not a magic wand—and the difference between those two framings is most of what determines whether it works.

This article is for educational and informational purposes only and is not medical advice. Tesamorelin (Egrifta) is a prescription medication; the FDA-approved indication is for HIV-associated lipodystrophy, and many of the uses discussed here are off-label. Self-administration of prescription peptides outside a clinical relationship carries real risks, and “research-grade” material sold outside the prescription framework is not quality-controlled for human use. Do not start, stop, dose, or cycle any peptide without the guidance of a qualified, licensed healthcare provider who can evaluate your individual history, contraindications, and bloodwork.

Property Support

Our Property Support services are designed to help homeowners, property managers, and businesses maintain safe, clean, and well-functioning properties year-round.

Get In Touch